Ab­b­Vie’s new AI deal; Roche's PhI­II win in breast can­cer; Spring­Works to raise $275M

Plus, news about Eli­go Bio­science, Eye­Point, Xenon and Merus:

Ab­b­Vie signs AI pact: For $30 mil­lion up­front, the phar­ma is part­ner­ing with BigHat Bio­sciences to de­vel­op new an­ti­bod­ies in on­col­o­gy and neu­ro­science. It’s the sec­ond bio­phar­ma AI al­liance to be an­nounced on Tues­day. Ab­b­Vie could dish out up to $325 mil­lion more in R&D mile­stones. — Kyle LaHu­cik

Roche touts PhI­II breast can­cer win for PI3K al­pha drug: The Big Phar­ma’s in­avolis­ib plus Pfiz­er’s Ibrance achieved a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in the pri­ma­ry end­point of pro­gres­sion-free sur­vival in peo­ple with PIK3CA-mu­tat­ed HR-pos­i­tive HER2-neg­a­tive ad­vanced or metasta­t­ic dis­ease. Roche plans to present the full da­ta at a fu­ture meet­ing and then sub­mit them to health au­thor­i­ties. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER